News

The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip
CRISPR Therapeutics has the potential to generate significant breakthroughs in gene editing. Regeneron's biggest growth ...
Hemoglobinopathies Market to Reach USD 25.68 Billion by 2032, Fueled by Gene Therapy Advances and Rising Newborn Screening Programs.
Innovations in gene editing, expanding global diagnostic infrastructure, and strong government initiatives are driving the hemoglobinopathies market's projected 11.56% CAGR through 2032, according to ...